Phaseline

Companies › Hansoh BioMedical R&D Company

Hansoh BioMedical R&D Company: clinical trials, targets and expected readouts

9 active drug programs in 25 registered trials: 15 Phase 1, 7 Phase 2, 3 Phase 3; Oncology, Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HS-20093
anti-B7-H3 antibody-drug conjugate
B7H3, CD276Phase 3Osteosarcoma; Small Cell Lung Cancer; Advanced Solid Tumor; Head and Neck Squamous Cell Carcinoma …Dec 2026
HS-20089
Anti-B7-H4 antibody-drug conjugate with topoisomerase I inhibitor payload
B7H4Phase 3Ovarian Cancer; Advanced Solid TumorsMar 2027
HS-20117-2 Injection
EGFR-MET bispecific antibody
EGFR, METPhase 2Non-Squamous Non-Small Cell Lung Cancer; Solid Tumors; Advanced Solid TumorsDec 2026
HS-20137–Phase 2Moderate-to-severe Plaque PsoriasisMar 2027
HS-20110–Phase 1Solid Tumors; CRCDec 2026
HS-20124
anti-CDH6 antibody-drug conjugate (DAR-8)
CDH6Phase 1Solid CancerDec 2026
HRS-5041
Androgen receptor PROTAC degrader
ARPhase 1Advanced Prostate CancerDec 2027
HS-20122–Phase 1Advanced Solid Tumors; Lung CancerJan 2028
HS-20108–Phase 1Advanced Solid TumorAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06935409HS-20093Phase 3OsteosarcomaOncologyJun 2026
NCT07186452HS-20093Phase 1Advanced Solid TumorsOncologyJul 2026
NCT06498479HS-20093Phase 3Small Cell Lung CancerOncologyAug 2026
NCT06621563HS-20117-2 InjectionPhase 1Solid TumorsOncologyDec 2026
NCT06112704HS-20093Phase 2Advanced Solid TumorOncologyDec 2026
NCT07462923HS-20093Phase 1Advanced Gastric and Gastroesophageal Junction AdenocarcinomaOncologyDec 2026
NCT06825624HS-20093Phase 1Metastatic Colorectal Cancer (CRC)OncologyDec 2026
NCT06763159HS-20124Phase 1Solid CancerOncologyDec 2026
NCT06892379HS-20110Phase 1Solid TumorsOncologyDec 2026
NCT07879885HS-20137Phase 2Moderate-to-severe Plaque PsoriasisImmunologyMar 2027
NCT06855069HS-20089Phase 3Ovarian CancerOncologyMar 2027
NCT06007729HS-20093Phase 2Head and Neck Squamous Cell CarcinomaOncologyDec 2027
NCT07115446HS-20093Phase 1Advanced Prostate CancerOncologyDec 2027
NCT07115446HRS-5041Phase 1Advanced Prostate CancerOncologyDec 2027
NCT07775703HS-20117-2 InjectionPhase 1Advanced Solid TumorsOncologyDec 2027
NCT05830123HS-20093Phase 2OsteosarcomaOncologyDec 2027
NCT06014190HS-20089Phase 2Ovarian CancerOncologyDec 2027
NCT06927570HS-20122Phase 1Advanced Solid TumorsOncologyJan 2028
NCT07824882HS-20093Phase 2Non-Small Cell Lung CancerOncologyMar 2028
NCT06336707HS-20089Phase 1Advanced Solid TumorsOncologyApr 2028
NCT06332170HS-20093Phase 1Advanced Solid TumorOncologyMay 2028
NCT06936735HS-20108Phase 1Advanced Solid TumorOncologyAug 2028
NCT07645222HS-20122Phase 1Lung CancerOncologyOct 2028
NCT07283367HS-20110Phase 1CRCOncologyDec 2029
NCT06417008HS-20117-2 InjectionPhase 2Non-Squamous Non-Small Cell Lung CancerOncologyJun 2030

Targets

B7H3 (1) CD276 (1) AR (1) CDH6 (1) B7H4 (1) EGFR (1) MET (1)

Companies with the same targets

AstraZeneca Beijing Biotech Johnson & Johnson (Janssen) Shanghai Henlius Biotech Phrontline Biopharma Novartis Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Qilu Pharmaceutical

Companies built like this

Pierre Fabre Medicament Avistone Biotechnology Shanghai JMT-Bio CSPC Megalith Biopharmaceutical Abbisko Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.